Natriuretic peptide-guided management of patients with heart failure: A decade of progress but still a controversy

Future Cardiology

Volumn 6, Issue 6, 2010, Pages 743-747

  Baibars, Motaz ^a   Ibrahim, Ahmed ^a   Fang, James C ^b   Sipahi, Ilke ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

biomarkers; heart failure; natriuretic peptide

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN; NATRIURETIC FACTOR; ROLOFYLLINE;

ACUTE HEART FAILURE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERCHOLESTEROLEMIA; MAXIMUM TOLERATED DOSE; PACEMAKER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SYSTOLIC HEART FAILURE; THERAPY EFFECT;

ADRENERGIC BETA-ANTAGONISTS; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; PROGNOSIS; RISK ASSESSMENT; TIME FACTORS;

EID: 78650207698     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.104     Document Type: Review

References (40)

1. Bonow RO, Bennett S, Casey DE Jr et al.; American College of Cardiology; American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures); Heart Failure Society of America: ACC/AHA clinical performance measures for adults with chronic heart failure: a report of the American College of Cardiology/ American Heart Association Task Force on Performance Measures (Writing Committee to Develop Heart Failure Clinical Performance Measures) endorsed by the Heart Failure Society of America. J. Am. Coll. Cardiol. 46(6), 1144-1178 (2005). (Pubitemid 41316528)
2. Fonarow GC, Abraham WT, Albert NM et al.: Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297(1), 61-70 (2007).
3. Maisel AS, Krishnaswamy P, Nowak RM et al.: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347(3), 161-167 (2002).
4. Januzzi JL Jr, Camargo CA, Anwaruddin S et al.: The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 95(8), 948-954 (2005).
5. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A: N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110(15), 2168-2174 (2004).
6. Hunt SA, Abraham WT, Chin MH et al.; American College of Cardiology Foundation; American Heart Association: 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119(14), E391-E479 (2009).
7. Tang WH, Francis GS, Morrow DA et al.; National Academy of Clinical Biochemistry Laboratory Medicine: National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116(5), E99-E109 (2007).
8. Maisel A: Natriuretic peptide-guided therapy for heart failure: ready for "battle" or too "scarred" by the challenges of trial design ?J. Am. Coll. Cardiol. 55(1), 61-64 (2009).
9. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H et al.: A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 28(1), 89-94 (1981).
10. Kangawa K, Matsuo H: Purifcation and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (a-hANP). Biochem. Biophys. Res. Commun. 118(1), 131-139 (1984). (Pubitemid 14191955)
11. Sudoh T, Kangawa K, Minamino N, Matsuo H: A new natriuretic peptide in porcine brain. Nature 332(6159), 78-81 (1988).
12. Morrow DA, de Lemos JA: Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115(8), 949-952 (2007).
13. Packer M: Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation 108(24), 2950-2953 (2003).
14. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355(9210), 1126-1130 (2000).
15. Lainchbury JG, Troughton RW, Strangman KM et al.: N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J. Am. Coll. Cardiol. 55(1), 53-60 (2009).
16. Jourdain P, Jondeau G, Funck F et al.: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49(16), 1733-1739 (2007).
17. Chen WC, Tran KD, Maisel AS: Biomarkers in heart failure. Heart 96(4), 314-320 (2010).
18. O'Donoghue M, Braunwald E: Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat. Rev. Cardiol. 2010(7), 13-20 (2010).
19. Maisel A: B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev. Cardiovasc. Med. 3(Suppl. 4), S10-S17 (2002).
20. Bhardwaj A, Januzzi JL Jr: Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. Crit. Pathw. Cardiol. 8(4), 146-150 (2009).
21. Yoshimura M, Mizuno Y, Nakayama M et al.: B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am. J. Med. 112(9), 716-720 (2002).
22. Latini R, Masson S, Anand I et al.; Valsartan Heart Failure Trial Investigators: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106(19), 2454-2458 (2002).
23. Tsutamoto T, Wada A, Maeda K et al.: Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol. 37(5), 1228-1233 (2001).
24. Cleland JG, Daubert JC, Erdmann E et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators: The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352(15), 1539-1549 (2005).
25. Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW: Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113(7), 977-985 (2006).
26. Stanek B, Frey B, Hülsmann M et al.: Prognostic evaluation of neurohumoral plasma levels before and during b-blocker therapy in advanced left ventricular dysfunction. J. Am. Coll. Cardiol. 38(2), 436-442 (2001).
27. Packer M, Poole-Wilson PA, Armstrong PW et al.: Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100(23), 2312-2318 (1999).
28. Konstam MA, Neaton JD, Dickstein K et al.; HEAAL Investigators: Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374(9704), 1840-1848 (2009).
29. Shah MR, Claise KA, Bowers MT et al.: Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am. Heart J. 150(5), 893-898 (2005).
30. Cleland JG, Coletta A P, Yassin A, Buga L, Torabi A, Clark AL: Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF. Eur. J. Heart Fail. 11(8), 802-805 (2009).
31. Eurlings L: Can pro-brain natriuretic peptide-guided therapy of heart failure improve heart failure morbidity and mortality? Main outcome of the PRIMA study. Presented at: ACC 58th Annual Scientifc Session. Orlando, USA, 29-31 March 2009.
32. Berger R, Moertl D, Peter S et al.: N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J. Am. Coll. 55(7), 645-653 (2010).
33. Pfsterer M, Buser P, Rickli H et al.; TIME-CHF Investigators: BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensifed vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301(4), 383-392 (2009).
34. Schou M, Gustafsson F, Videbaek L et al.: Design and methodology of the NorthStar Study: NT-proBNP stratifed follow-up in outpatient heart failure clinics - a randomized Danish multicenter study. Am. Heart J. 156(4), 649-655 (2008).
35. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM: Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am. Heart J. 158(3), 422-430 (2009).
36. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H: B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch. Intern. Med. 170(6), 507-514 (2010).
37. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H: BNP-guided therapy not better than expert's clinical assessment for b-blocker titration in patients with heart failure. Congest. Heart Fail. 11(5), 248-253; quiz 254-255 (2005).
38. Anguita M, Esteban F, Castillo JC et al.: [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure.]. Med. Clin. (Barc.) 135(10), 435-440 (2010).
39. Yusuf S, Pfeffer MA, Swedberg K et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386), 777-781 (2003).
40. Fonarow GC, Stough WG, Abraham WT et al.; OPTIMIZE-HF Investigators and Hospitals: Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol. 50(8), 768-777 (2007).